NR vs NMN vs NAD+: what are you buying?

Three names, three different purchases

NAD+ is the coenzyme that appears in descriptions of cellular energy metabolism. NR and NMN are precursors studied as ways to support NAD+ production. The distinction matters because a checkout page may say NAD support in its headline while the ingredient panel names a precursor. That is a different purchase from a product containing NAD+ itself. Read the ingredient panel and the route together before using the price as a comparison.

A familiar abbreviation is not an ingredient specification. A blend can contain several compounds, and a label can describe the amount of the whole blend rather than the amount of each ingredient. Ask for the precise active ingredient and its stated quantity. If that information is unavailable before payment, the comparison is incomplete. A claim about cellular energy cannot supply the missing product details.

What the human precursor studies show

The 2018 Martens trial tested oral NR in healthy middle-aged and older adults. It found changes in NAD+ metabolism and assessed short-term tolerability. The 2021 Yoshino trial studied oral NMN in postmenopausal women with prediabetes who were overweight or obese, reporting an improvement in a specific measure of muscle insulin sensitivity. These are different populations and outcomes, rather than two products tested against each other.

Comparing the headlines from those trials cannot identify a winner. To do that reliably, researchers would need a suitable direct comparison, a defined population and a meaningful shared outcome. Even then, the result would apply to the formulations and conditions tested. A retailer combining the best finding from each separate study is presenting a marketing narrative, not a clinical comparison.

Why the delivery route changes the question

A capsule, a skin patch, an injection and an IV infusion are separate delivery systems. A trial of an oral ingredient does not measure the absorption of a patch. It does not address the quality of a compounded injectable product either. The label may refer to the same biochemical pathway, but the questions about exposure, manufacturing and clinical supervision differ.

The 2019 Grant infusion pilot measured plasma and urine metabolites during and after intravenous NAD+. Its purpose and findings concern what happened to an infused molecule. They cannot be substituted for a trial demonstrating a sustained improvement in fatigue, memory or lifespan. Read the study question before accepting an infusion provider's summary of it.

How to compare two product pages

Start with a small written comparison: exact ingredient, route, amount disclosed, what one purchase includes, and the outcome the seller promises. Then check whether the cited study used that ingredient by that route. An expensive product does not become more credible because it has more references; the references have to address the actual purchase.

Keep evidence and convenience separate. A subscription may be easier to manage, or a seller may explain its cancellation terms more clearly, without having a better clinical product. Likewise, a lower price does not resolve an evidence gap. A useful comparison can identify what is known about the purchase while leaving the question of personal medical suitability to a licensed clinician.

• Does the ingredient panel name NAD+, NR, NMN, or a blend?
• Was the cited research conducted in people using the same route?
• Did it measure a health outcome or a laboratory marker?
• Can you see the full commitment and cancellation terms before paying?

There is no universal best option

The right conclusion from a limited evidence base is narrower than a best-supplement ranking. Different trials investigate different questions. A result in people with a defined metabolic problem does not establish the same benefit for healthy younger adults, and a short observation period cannot establish years of safety. Treat those boundaries as part of the finding.

If you are considering a product because of a symptom, start with the symptom rather than the molecule. Ask a clinician whether an established evaluation or treatment should come first. Bring the exact label and the specific claim you are trying to verify. That creates a more useful conversation than asking which NAD booster is strongest.

Sources and scope

These are selected studies and official sources relevant to the question above, rather than a systematic review of every published paper. A finding applies to the people, ingredient, route and outcomes studied. This guide provides education, not a diagnosis or medical advice. Discuss personal treatment decisions with a licensed clinician.

1. Martens CR and 7 others, Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun, 2018. PubMed 29599478. Read the PubMed record
2. Yoshino M and 10 others, Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 2021. PubMed 33888596. Read the PubMed record
3. Grant R and 6 others, A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. Front Aging Neurosci, 2019. PubMed 31572171. Read the PubMed record

Continue reading

• Understanding NAD+ blood tests

  Sample types, reference intervals and practical questions to ask before paying for a laboratory package.

• NAD+ and anti-aging evidence

  Separate short human trials, laboratory findings and lifespan promises before evaluating a longevity claim.

• NAD+ supplement quality and COAs

  How to match a certificate of analysis to a product and batch, and what quality testing cannot establish.

All NAD+ research guides